'Passive stabilization' of striatal extracellular dopamine across the lesion spectrum encompassing the presymptomatic phase of Parkinson's disease: A voltammetric study in the 6-OHDA-lesioned rat

Journal of Neurochemistry

Volumn 87, Issue 5, 2003, Pages 1224-1236

  Bergstrom, Brian P ^a   Garris, Paul A ^b  

^a MUSKINGUM COLLEGE   (United States)

^b ILLINOIS STATE UNIVERSITY   (United States)

Author keywords

Compensation; Dopamine; Parkinson's disease; Release; Uptake; Voltammetry

Indexed keywords

CARBON FIBER; DOPAMINE; OXIDOPAMINE;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; CYCLIC POTENTIOMETRY; DISEASE COURSE; DISEASE MODEL; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; ELECTROSTIMULATION; MALE; MICROELECTRODE; NERVE CELL PLASTICITY; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STEADY STATE; SYNAPTIC TRANSMISSION;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINE; ELECTRIC STIMULATION; ELECTROCHEMISTRY; ELECTRODES, IMPLANTED; EXTRACELLULAR FLUID; KINETICS; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 0344442860     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.02104.x     Document Type: Article

References (80)

1. Abercrombie E. D., Bonatz A. E. and Zigmond M. J. (1990) Effects of L-Dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res. 525, 36-44.
2. Agid Y. (1991) Parkinson's disease: pathophysiology. Lancet 337, 1321-1324.
3. Altar C. A., Marien M. R. and Marshall J. F. (1987) Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J. Neurochem. 48, 390-399.
4. Annett L. E., Smyly R. E., Henderson J. M., Cummings R. M., Kendall A. L. and Dunnett S. B. (2000) Behavioral assessment in the unilateral dopamine-depleted marmoset, in Central Nervous System Diseases - Innovative Animal Models from Lab to Clinic (Emerich D. F., Dean R. L. III and Sanberg P. R., eds), pp. 171-186. Humana Press, Totowa.
5. Bath B. D., Michael D. J., Trafton B. J., Joseph J. D., Runnels P. L. and Wightman R. M. (2000) Subsecond adsorption and desorption of dopamine at carbon-fiber microelectrodes. Anal. Chem. 72, 5994-6002.
6. Bergstrom B. P. and Garris P. A. (1999) Utility of a tripolar stimulating electrode for eliciting dopamine release in the rat striatum. J. Neurosci. Meth. 87, 201-208.
7. Bergstrom B. P., Schertz K. E., Weirick T., Nafziger B., Takacs S. A., Lopes K. O., Massa K. J., Walker Q. D. and Garris P. A. (2001) Partial, graded losses of dopamine terminals in the rat caudate-putamen: an animal model for the study of compensatory adaptation in preclinical parkinsonism. J. Neurosci. Meth. 106, 15-28.
8. Bezard E. and Gross C. E. (1998) Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog. Neurobiol. 55, 93-116.
9. Bezard E., Jaber M., Gonon F., Boireau A., Bloch B. and Gross C. E. (2000) Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur. J. Neurosci. 12, 2892-2900.
10. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A. R., Bioulac B., Brotchie J. M. and Gross C. E. (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21, 6853-6861.
11. Bezard E., Gross C. E. and Brotchie J. M. (2003) Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 26, 215-221.
12. Bjorklund A. and Lindvall O. (1984) Dopamine-containing systems in the CNS, in Handbook of Chemical Neuroanatomy (Bjorklund A. and Hokfelt T., eds), pp. 55-122. Elsevier, New York.
13. Cahill P. S., Walker Q. D., Finnegan J. M., Mickelson G. E., Travis E. R. and Wightman R. M. (1996) Microelectrodes for the measurement of catecholamines in biological systems. Anal. Chem. 68, 3180-3186.
14. Cline E. J., Adams C. E., Larson G. A., Gerhardt G. A. and Zahniser N. R. (1995) Medial dorsal striatum is more sensitive than lateral dorsal striatum to cocaine inhibition of exogenous dopamine clearance: relation to [3H]mazindol binding, but not striosome/matrix. Exp. Neurol. 134, 135-149.
15. Dentresangle C., Le Cavorsin M., Savasta M. and Leviel V. (2001) Increased extracellular DA and normal evoked DA release in the rat striatum after a partial lesion of the substantia nigra. Brain Res. 893, 178-185.
16. Doucet G., Descarries L. and Garcia S. (1986) Quantification of the dopamine innervation in adult rat neostriatum. Neuroscience 19, 427-445.
17. Eshleman A. J., Wolfrum K., Mash D. C., Christensen K. and Janowsky A. (2001) Drug interactions with the dopamine transporter in cryopreserved human caudate. J. Pharmacol. Exp. Ther. 296, 442-449.
18. Fallon J. H. and Moore R. Y. (1978) Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J. Comp. Neurol. 180, 545-580.
19. Fernandez A., de Ceballos M. L., Rose S., Jenner P. and Marsden C. D. (1996) Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease. Brain 119, 823-830.
20. Freed C. R., Greene P. E., Breeze R. E. et al. (2001) Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344, 710-719.
21. Gage F. H. (2000) Mammalian neural stem cells. Science 287, 1433-1438.
22. Garris P. A. and Rebec G. V. (2002) Modeling fast dopamine neurotransmission in the nucleus accumbens during behavior. Behav Brain Res. 137, 47-63.
23. Garris P. A. and Wightman R. M. (1994) Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J. Neurosci. 14, 442-450.
24. Garris P. A., Ciolkowski E. L., Pastore P. and Wightman R. M. (1994a) Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J. Neurosci. 14, 6084-6093.
25. Garris P. A., Ciolkowski E. L. and Wightman R. M. (1994b) Heterogeneity of evoked dopamine overflow within the striatal and striatoamygdaloid regions. Neuroscience 59, 417-427.
26. Garris P. A., Walker Q. D. and Wightman R. M. (1997) Dopamine release and uptake rates both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals. Brain Res. 753, 225-234.
27. Gerfen C. R., Herkenham M. and Thibault J. (1987) The neostriatal mosaic. II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J. Neurosci. 7, 3915-3934.
28. Gerlach M. and Riederer P. (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 103, 987-1041.
29. Grace A. A. (2000) The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psycho-stimulant craving. Addiction 95, S119-S128.
30. Hefti F., Enz A. and Melamed E. (1985) Partial lesions of the nigro-striatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs. Neuropharmacology 24, 19-23.
31. Hollerman J. R. and Grace A. A. (1990) The effects of dopamine-depleting brain lesions on the electrophysiological activity of rat substantia nigra dopamine neurons. Brain Res. 533, 203-212.
32. Hooks M. S., Juncos J. L., Justice J. B. Jr, Meiergerd S. M., Povlock S. L., Schenk J. O. and Kalivas P. W. (1994) Individual locomotor response to novelty predicts selective alterations in D1 and D2 receptors and mRNAs. J. Neurosci. 14, 6144-6152.
33. van Home C., Hoffer B. J., Stromberg I. and Gerhardt G. A. (1992) Clearance and diffusion of locally applied dopamine in normal and 6-hydroxydopamine-lesioned rat striatum. J. Pharmacol. Exp. Ther. 263, 1285-1292.
34. Homykiewicz O. (1966) Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18, 925-964.
35. Homykiewicz O. and Kish S. J. (1987) Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45, 19-34.
36. Hyland B., Reynolds J., Hay J., Perk C. and Miller R. (2002) Firing modes of midbrain dopamine cells in the freely moving rat. Neuroscience 114, 475.
37. Jones S. R., Gainetdinov R. R., Jaber M., Giros B., Wightman R. M. and Caron M. G. (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl Acad. Sci. USA 95, 4029-4034.
38. Joyce J. N., Smutzer G., Whitty C. J., Myers A. and Bannon M. J. (1997) Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Mov. Disord. 12, 885-897.
39. Kawagoe K. T., Garris P. A., Wiedemann D. J. and Wightman R. M. (1992) Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum. Neuroscience 51, 55-64.
40. Kirik D., Rosenblad C. and Bjorklund A. (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152, 259-277.
41. Kordower J. H., Emborg M. E., Bloch J. et al. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773.
42. Lang A. E. and Lozano A. M. (1998) Parkinson's disease. Second of two parts. N. Engl. J. Med: 339, 1130-1143.
43. Marshall J. F., O'Dell S. J., Navarrete R. and Rosenstein A. J. (1990) Dopamine high-affinity transport site topography in rat brain: major differences between dorsal and ventral striatum. Neuroscience 37, 11-21.
44. Mazzoni P. and Ford B. (1999) The freezing of time as a presenting symptom of Parkinson's disease. N. Engl. J. Med. 341, 1317-1318.
45. McCauley P. G., O'Boyle K. M. and Waddington J. L. (1995) Dopamine-induced reduction in the density of guanine nucleotide-sensitive D1 receptors in human postmortem brain in the absence of apparent D1: D2 interactions. Neuropharmacology 34, 777-783.
46. Michael D., Travis E. R. and Wightman R. M. (1998) Color images for fast-scan CV measurements in biological systems. Anal. Chem. 70, 586A-592A.
47. Michael D. J., Joseph J. D., Kilpatrick M. R., Travis E. R. and Wightman R. M. (1999) Improving data acquisition for fast-scan cyclic voltammetry. Anal. Chem. 71, 3941-3947.
48. Nirenberg M. J., Vaughan R. A., Uhl G. R., Kuhar M. J. and Pickel V. M. (1996) The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J. Neurosci. 16, 436-447.
49. Obeso J. A., Olanow C. W. and Nutt J. G. (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23, S2-S7.
50. Olanow C. W. and Tatton W. G. (1999) Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22, 123-144.
51. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
52. Phillips P. E., Stuber G. D., Heien M. L., Wightman R. M. and Carelli R. M. (2003) Subsecond dopamine release promotes cocaine seeking. Nature 422, 614-618.
53. Pickel V. M., Johnson E., Carson M. and Chan J. (1992) Ultrastructure of spared dopamine terminals in caudate-putamen nuclei of adult rats neonatally treated with intranigral 6-hydroxydopamine. Brain Res. Dev. Brain Res. 70, 75-86.
54. Pierce J. P. and Lewin G. R. (1994) An ultrastructural size principle. Neuroscience 58, 441-446.
55. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
56. Ridd M. J., Kitchen I. and Fosbraey P. (1998) The effect of acute kainic acid treatment on dopamine D2 receptors in rat brain. Neurosci. Res. 30, 201-211.
57. Robinson D. L., Phillips P. E., Budygin E. A., Traflon B. J., Garris R. A. and Wightman R. M. (2001) Sub-second changes in accumbal dopamine during sexual behavior in male rats. Neuroreport 12, 2549-2552.
58. Robinson T. E., Mocsary Z., Camp D. M. and Whishaw I. Q. (1994) Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system. J. Neurosci. 14, 2687-2696.
59. Rothblat D. S. and Schneider J. S. (1999) Regional differences in striatal dopamine uptake and release associated with recovery from MPTP-induced parkinsonism: an in vivo electrochemical study. J. Neurochem. 72, 724-733.
60. Schallert T., Fleming S. M., Leasure J. L., Tillerson J. L. and Bland S. T. (2000) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39, 777-787.
61. Schneider J. S., Rothblat D. S. and DiStefano L. (1994) Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism. Brain Res. Mol Brain Res. 643, 86-91.
62. Schultz W. (1998) Predictive reward signal of dopamine neurons. J. Neurophysiol. 80, 1-27.
63. Schwarting R. K. and Huston J. P. (1996) The unilateral 6-hydroxy-dopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50, 275-331.
64. Sesack S. R., Aoki C. and Pickel V. M. (1994) Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J. Neurosci. 14, 88-106.
65. Shimura H., Schlossmacher M. G., Hattori N., Frosch M. P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K. S. and Selkoe D. J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263-269.
66. Snyder G. L., Keller R. W. Jr and Zigmond M. J. (1990) Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals. J. Pharmacol. Exp. Ther. 253, 867-876.
67. Sokal R. R. and Rohlf F. J. (1995) Biometry: The Principles and Practice of Statistics in Biological Research. W.H. Freeman, New York.
68. Stachowiak M. K., Keller R. W. J., Stricker E. M. and Zigmond M. J. (1987) Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage. J. Neurosci. 7, 1648-1654.
69. Uhl G. R., Walther D., Mash D., Faucheux B. and Javoy-Agid F. (1994) Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann. Neurol. 35, 494-498.
70. Vizi E. S. (2000) Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacol. Rev. 52, 63-89.
71. Wightman R. M., Amatore C., Engstrom R. C., Hale P. D., Kristensen E. W., Kuhr W. G. and May L. J. (1988) Real-time characterization of dopamine overflow and uptake in the rat striatum. Neuroscience 25, 513-523.
72. Wolf M. E., Zigmond M. J. and Kapatos G. (1989) Tyrosine hydroxylase content of residual striatal dopamine nerve terminals following 6-hydroxydopamine administration: a flow cytometric study. J. Neurochem. 53, 879-885.
73. Wu Q., Reith M. E., Kuhar M. J., Carroll F. I. and Garris P. A. (2001a) Preferential increases in nucleus accumbens dopamine after systemic cocaine administration are caused by unique characteristics of dopamine neurotransmission. J. Neurosci. 21, 6338-6347.
74. Wu Q., Reith M. E., Wightman R. M., Kawagoe K. T. and Garris P. A. (2001b) Determination of release and uptake parameters from electrically evoked dopamine dynamics measured by real-time voltammetry. J. Neurosci. Meth 112, 119-133.
75. Zhang W. Q., Tilson H. A., Nanry K. P., Hudson P. M., Hong J. S. and Stachowiak M. K. (1988) Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res. 461, 335-342.
76. Zigmond M. J. (1997) Do compensatory processes underlie the pre-clinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism. Neurobiol. Dis. 4, 247-253.
77. Zigmond M. J., Acheson A. L., Stachowiak M. K. and Stricker E. M. (1984) Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch. Neurol. 41, 856-861.
78. Zigmond M. J., Abercrombie E. D., Berger T. W., Grace A. A. and Stricker E. M. (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13, 290-296.
79. Zigmond M. J., Hastings T. G. and Abercrombie E. D. (1992) Neurochemical responses to 6-hydroxydopamine and L-Dopa therapy: implications for Parkinson's disease. Ann. N. Y. Acad. Sci. 648, 71-86.
80. Zoli M., Torri C., Ferrari R., Jansson A., Zini I., Fuxe K. and Agnati L. F. (1998) The emergence of the volume transmission concept. Brain Res. Brain Res. Rev. 26, 136-147.